Theragenics Completes Acquisition of NeedleTech Products
Theragenics Corporation(R) (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, announced today that it completed the acquisition of NeedleTech Products, Inc., on July 28, 2008. The agreement to acquire NeedleTech for $47.8 million was previously announced by Theragenics on July 16, 2008.
With revenue of $16.9 million in 2007, NeedleTech, located in Attleboro, MA, is a manufacturer of specialty needles and related medical devices. Its current products include coaxial needles, biopsy needles, access trocars, brachytherapy needles, guidewire introducer needles, spinal needles, disposable veress needles, and other needle-based products. End markets served include the cardiology, orthopedic, pain management, endoscopy, spine, urology, and veterinary markets.
Theragenics paid $47.8 million in cash, plus its transaction costs, for NeedleTech, subject to the terms and conditions of the agreement. Theragenics retained the cash and investments held by NeedleTech, which totaled approximately $5.0 million as of June 30, 2008. The purchase price is also subject to a working capital adjustment. Theragenics financed $24.5 million of the purchase price with borrowings on its existing $40.0 million credit facility and paid the remainder from current cash and investment balances. Theragenics expects the acquisition to be dilutive to earnings per share in 2008 and accretive in 2009. The results of operations of NeedleTech will be included in Theragenics’ consolidated results beginning July 28, 2008.
Theragenics hosted a conference call on July 17, 2008, to discuss the NeedleTech acquisition. A replay of this conference call is available on Theragenics’ Web site, www.theragenics.com, until October 31, 2008.
Genesis Capital was the Company’s financial advisor, and Powell Goldstein LLP was the Company’s legal advisor on this transaction.
Theragenics Corporation (NYSE: TGX) operates two business segments: its surgical products business and its brachytherapy seed business. Its surgical products business (www.cpmedical.com, www.galtmedical.com, www.needletech.com) manufactures and distributes wound closure, vascular access, and specialty needle products. Wound closure products include sutures, needles and other surgical products. Vascular access includes introducers, guidewires and related products. Specialty needles include coaxial, biopsy, spinal and disposable veress needles, access trocars, and other needle based products. The Company’s surgical products segment serves a number of markets and applications, including, among other areas, interventional cardiology, interventional radiology, vascular surgery, orthopedics, plastic surgery, dental, urology, veterinary, pain management, endoscopy, and spine. The brachytherapy business manufactures and markets its premier product, the palladium-103 TheraSeed(R) device (www.theraseed.com) and I-Seed, an iodine-125 based device, which are used primarily in the minimally invasive treatment of localized prostate cancer. For additional information, call Theragenics’ Investor Relations Department at (800) 998-8479 or visit www.theragenics.com.
This press release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding the contribution of NeedleTech Products, Inc. to Theragenics sales, impact on net income, future growth and anticipated positive results in general. Actual results may differ materially due to a variety of factors, risks and uncertainties including, without limitation, the ability to successfully integrate NeedleTech into the Theragenics organization, capitalization on opportunities for growth within the NeedleTech business plan, ability to recognize value from areas of shared expertise, risks and uncertainties related to competition within the medical device industry, development and growth of new applications within the markets for needles, vascular access, wound closure, brachytherapy and more broadly, medical devices, competition from other companies within the needle, vascular access, wound closure and medical device markets, competition from other methods of treatment, new product and process development cycles, potential costs and delays associated with expansion and executing growth strategies, potential costs and delays in production optimization, effectiveness and execution of marketing and sales programs, changes in pricing of raw materials or changes in relationships with key suppliers, third-party (including CMS) reimbursement, Congressional action affecting Medicare reimbursement, physician training, third-party distribution agreements, and other factors set forth from time to time in the Company’s Securities and Exchange Commission filings.
All forward looking statements and cautionary statements included in this document are made as of the date hereof based on information available to the Company as of the date hereof, and the Company assumes no obligation to update any forward looking statement or cautionary statement.